序号 |
标题 |
次数 |
作者 |
发布时间 |
75691 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
106 |
h |
2024-12-19 |
75692 |
cas:252554-78-2,Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH,(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
61 |
kx |
2024-12-19 |
75693 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
98 |
h |
2024-12-19 |
75694 |
cas:2413428-36-9,MC-Gly-Gly-Phe-Gly,(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
83 |
kx |
2024-12-19 |
75695 |
MC-Val-Cit-PAB-PNP CAS:159857-81-5 |
127 |
zyl |
2024-12-19 |
75696 |
cas:2353409-52-4,Mal-amido-PEG8-Val-Gly-PAB-OH,马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 |
72 |
kx |
2024-12-19 |
75697 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
76 |
zyl |
2024-12-19 |
75698 |
cas:1895916-22-9,MC-Val-Ala-OH, ADC试剂 |
71 |
kx |
2024-12-19 |
75699 |
cas:159857-70-2,MC-Val-Cit-Doxorubicin,MC-VAL-CIT-阿霉素 |
65 |
kx |
2024-12-19 |
75700 |
DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 |
75 |
h |
2024-12-19 |
75701 |
DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 |
85 |
h |
2024-12-19 |
75702 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE), N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) |
97 |
kx |
2024-12-19 |
75703 |
DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 |
106 |
h |
2024-12-19 |
75704 |
DOTA-MGO DOTA-DGlu-(Glu)s-minigastrin |
79 |
h |
2024-12-19 |
75705 |
cas:2762518-86-3,NHS Ester-PEG4-Val-Cit-PAB-MMAE, ADC试剂 |
128 |
kx |
2024-12-19 |
75706 |
DOTA-scFv-anti-PSMA DOTA-scFv-抗PSMA脂质纳米粒(LNPs) |
80 |
h |
2024-12-19 |
75707 |
cas:2353409-45-5,BCN-PEG3-Val-Cit-PFP Ester, ADC试剂 |
73 |
kx |
2024-12-19 |
75708 |
cas:2112738-13-1,Mal-amido-PEG2-Val-Cit-PAB-PNP, ADC试剂 |
78 |
kx |
2024-12-19 |
75709 |
cas:2055041-39-7,Mal-PEG4-Val-Cit-PAB-OH, ADC试剂 |
73 |
kx |
2024-12-19 |
75710 |
cas:2055024-62-7,NH2-PEG3-Val-Cit-PAB-OH, ADC试剂 |
127 |
kx |
2024-12-19 |
75711 |
Fmoc-PEG3-Val-Cit,N-芴甲氧羰基-三聚乙二醇-VAL-CIT |
99 |
kx |
2024-12-19 |
75712 |
DOTA-anti-VLA-4 |
82 |
h |
2024-12-19 |
75713 |
DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide |
83 |
h |
2024-12-19 |
75714 |
CAS: 2748039-76-9, Alkyne-Val-Cit-PAB-FAM,炔-Val-Cit-PAB-FAM |
76 |
WYQ |
2024-12-19 |
75715 |
CAS:646502-53-6 MC-Val-Cit-PAB-MMAE的结构式 |
111 |
zyl |
2024-12-19 |
75716 |
Amino-PEG2-VG-N-Bis(PEG1-azide),氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮) |
90 |
WYQ |
2024-12-19 |
75717 |
Azido-PEG8-Val-Cit-PAB-PNP,C34H47N9O12 |
93 |
WYQ |
2024-12-19 |
75718 |
化合物:TCO-MMAE,反式环辛烯-MMAE(其中MMAE为单甲基澳瑞他汀E的缩写) |
138 |
WYQ |
2024-12-19 |
75719 |
cas:2748039-77-0,Alkyne-Val-Cit-PAB-PNP,炔-VAL-CIT-PAB-PNP 酯 |
88 |
kx |
2024-12-19 |
75720 |
endo BCN-PEG3-Val-Cit,endo BCN-聚乙二醇3-缬氨酸-瓜氨酸,CAS号:1263166-91-1 |
113 |
WYQ |
2024-12-19 |
75721 |
cas:1803279-86-8,DBCO-C4-SulfoNHS ester, ADC试剂 |
76 |
kx |
2024-12-19 |
75722 |
Mal-PEG8-Val-Cit-PAB-MMAE CAS:2353409-69-3 |
87 |
zyl |
2024-12-19 |
75723 |
159857-80-4,MC-Val-Cit-PAB-OH,MC-VAL-CIT-PAB中间体 |
80 |
kx |
2024-12-19 |
75724 |
氨基-四聚乙二醇-Val-Cit-PAB-MMAE,Amino-PEG4-Val-Cit-PAB-MMAE,ADC定制 |
62 |
wyh |
2024-12-19 |
75725 |
CAS: 2748039-77-0,化合物:Alkyne-Val-Cit-PAB-PNP |
84 |
WYQ |
2024-12-19 |
75726 |
MAC glucuronide linker-2 CAS:229977-57-5 |
86 |
zyl |
2024-12-19 |
75727 |
DOTA-cPAM4 DOTA标记PAM4抗体 |
58 |
h |
2024-12-19 |
75728 |
PC SPDP-NHS carbonate ester, ADC试剂 |
129 |
kx |
2024-12-19 |
75729 |
Py-ds-Prp-OPFP的介绍 |
119 |
zyl |
2024-12-19 |
75730 |
cas:877864-04-5,THP-SS-alcohol, ADC试剂 |
67 |
kx |
2024-12-19 |
75731 |
MeO-DOTA−CC49 甲氧基DOTA偶联抗TAG-72单克隆抗体CC49 |
185 |
h |
2024-12-19 |
75732 |
Ala-Ala-Asn-PAB CAS:2149584-00-7 |
102 |
zyl |
2024-12-19 |
75733 |
cas:485800-27-9,Boc-NH-ethyl-SS-propionic acid, ADC试剂 |
100 |
kx |
2024-12-19 |
75734 |
cas:2228857-32-5,Azidoethyl-SS-propionic acid, ADC试剂 |
69 |
kx |
2024-12-19 |
75735 |
Fmoc-Val-Cit-PAB CAS:159858-22-7 |
124 |
zyl |
2024-12-19 |